Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

Analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Cheesecake Factory in a ...

Stephanie Braming, global head of William Blair Investment Management, plans to retire in the fourth quarter, a news release ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

At this past week’s ICR Conference in Orlando, cautious optimism floated beneath the current of two, inflation-strapped years ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock ...

Parsons Corp. (PSN) is sinking 9% today after investment bank William Blair cut its rating on the name to Market Perform from Outperform.

Fintel reports that on January 23, 2025, William Blair downgraded their outlook for Parsons (NYSE:PSN) from Outperform to Market Perform. Analyst Price Forecast Suggests 30.87% Upside As of December ...

Vertical Aerospace (Vertical) (NYSE: EVTL) ("Vertical" or the "Company"), a global aerospace and technology company that is ...

William Blair has recently reduced Applied Therapeutics Inc (APLT) stock to Mkt Perform rating, as announced on December 23, 2024, according to Finviz. Earlier, on December 2, 2024, UBS had reduced ...

Investing.com -- Parsons Corp . (NYSE: PSN) shares tumbled 9.5% as the market reacted to a downgrade from analysts at William Blair. The firm altered its rating on the defense and intelligence ...

Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.